Based on an increasing amount of experimental evidence showing their beneficial effects in animal disease models [1,2], sEH inhibitors have recently entered the first phases of clinical development for the treatment of various diseases, including hypertension, diabetes, stroke, dyslipidemia, pain, immunological disorders, neurological diseases, eye diseases, and other indications [3,4]. Here, EPHX2 is linked to diabetes mellitus.